サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1747746

ターゲットリポソームドラッグデリバリーの世界市場

Targeted Liposomes Drug Delivery

出版日
ページ情報
英文 181 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.42円
ターゲットリポソームドラッグデリバリーの世界市場
出版日: 2025年06月13日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ターゲットリポソームドラッグデリバリーの世界市場は2030年までに45億米ドルに達する見込み

2024年に27億米ドルと推定されるターゲットリポソームドラッグデリバリーの世界市場は、2024年から2030年にかけてCAGR 9.1%で成長し、2030年には45億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるリポソームドキソルビシンは、CAGR 9.8%を記録し、分析期間終了時には23億米ドルに達すると予測されます。リポソームパクリタキセルセグメントの成長率は、分析期間中CAGR 10.0%と推定されます。

米国市場は7億940万米ドルと推定、中国はCAGR 8.8％で成長すると予測

米国のターゲットリポソームドラッグデリバリー市場は、2024年に7億940万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 8.8%で推移し、2030年には7億2,380万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.4%と7.6%と予測されています。欧州では、ドイツがCAGR 7.2%で成長すると予測されています。

世界の「ターゲットリポソームドラッグデリバリー」市場- 主要動向と促進要因のまとめ

ドラッグデリバリーの精度を高めるリポソームとは？

標的リポソームは、精密医療における最も洗練されたツールの一つとして登場し、治療化合物を特定の細胞や組織に送達する方法に革命をもたらしています。これらのナノスケールの脂質ベースの小胞は、水性コアまたは脂質二重膜内に薬物をカプセル化し、バイオアベイラビリティを高め、毒性を低減し、制御放出を可能にします。活性薬剤を全身に無差別に分散させることが多い従来のドラッグデリバリー法とは異なり、標的化リポソームは、リガンド、抗体、ペプチド、アプタマーなどの表面修飾を用いて、特にがんや炎症性疾患などの疾患細胞に特異的に発現する受容体に結合します。

この選択性により、リポソームは、ドキソルビシンやパクリタキセルのような化学療法剤を腫瘍部位に直接送達し、健康な組織へのダメージを最小限に抑える、腫瘍学において非常に貴重なプラットフォームとなりました。ドキシルやオニバイドのようなFDA承認の製剤は、その臨床的有用性と治療効果を裏付けています。リポソームはまた、複数のドラッグデリバリーを可能にし、薬剤耐性に対処する相乗的治療に道を開きます。その生分解性と低い免疫原性は、繰り返し投与が必要な慢性疾患や再発性疾患に理想的です。薬理学とターゲティングの精度を融合させるこの革新的な能力は、標的リポソームを次世代ドラッグ・デリバリー・システムの最前線に押し上げています。

リポソームの機能性とターゲティング精度を高める技術革新とは？

技術の進歩により、リポソームの構築、機能化、展開方法が急速に洗練されつつあります。ポリエチレングリコールでコーティングされたPEG化リポソームの開発は、免疫系による迅速なクリアランスを防ぐことで、血流中での循環時間を延長しました。一方、リガンドを結合させたリポソームは、HER2+乳がん、EGFRを主成分とする肺がん、CD44を発現する白血病などの疾患で過剰発現している細胞マーカーに特異的に結合するように設計されています。このアプローチにより、細胞内への取り込みが促進され、標的部位での薬物の滞留が改善されます。

カプセル化技術も著しい進歩を遂げています。pH勾配やイオン勾配を利用した遠隔負荷法は、受動的手法と比較して薬物負荷効率と安定性が高いです。さらに、刺激応答性リポソーム（pH、温度、酵素、または外部放射線によってトリガーされる）は、空間的・時間的に制御された薬物放出を可能にし、特に微小環境条件が正常組織と異なる固形がんにおいて有用です。マイクロ流体技術により、リポソームの精密な製造が可能となり、臨床的有効性と再現性にとって極めて重要な、極めて均一なサイズ分布が得られるようになりました。このような科学的進歩により、リポソームはカスタマイズ可能な多機能ナノキャリアへと変貌を遂げつつあり、これまで困難であった薬理学的課題に対処できるようになりつつあります。

標的リポソームは現在、どこで最も大きな臨床的影響を及ぼしているか？

標的リポソームの臨床的インパクトが最も大きいのは、現在、腫瘍学、感染症治療、希少遺伝性疾患です。がん治療では、全身化学療法がしばしば用量制限毒性を引き起こす乳がん、卵巣がん、膵臓がん、肝臓がんの治療にリポソーム製剤が使用されています。リポソームは正常細胞を保護するだけでなく、腫瘍部位での薬物濃度を高め、治療効果を高めることができます。血液学的悪性腫瘍では、リポソームを用いたRNAi治療薬の送達が、疾患細胞内で直接がん遺伝子を抑制する遺伝子サイレンシング戦略を可能にしています。

がん領域以外でも、リポソームは真菌や細菌感染症の治療にも利用されつつあります。例えば、リポソーム型アムホテリシンBは、この強力な抗真菌薬の安全性プロファイルを劇的に改善し、免疫不全患者における主力薬となっています。遺伝子治療とmRNAデリバリーの分野では、リポソームがリピドナノ粒子（LNP）に応用されつつあり、これはCOVID-19 mRNAワクチンで重要な役割を果たし、その拡張性と翻訳力を証明しました。さらに、希少疾患治療では、正確な細胞内デリバリーが重要なライソゾーム貯蔵病や代謝障害に対処するため、リポソーム・プラットフォームが採用され始めています。リポソームはより安全で低用量であり、若年患者のコンプライアンスを向上させるため、小児への適用も拡大しています。標的リポソームの幅広い治療適用性により、リポソームは個別化された精密主導型薬物療法の要となっています。

ターゲットリポソームドラッグデリバリー市場の成長はいくつかの要因によって牽引される...

ターゲットリポソームドラッグデリバリー市場の成長は、医薬品イノベーション、標的治療に対する臨床需要の高まり、規制や患者の嗜好の変化に根ざしたいくつかの要因によって牽引されています。中でも、個別化医療への注目が高まっており、疾患の分子サブタイプを正確にターゲットとする送達システムが必要とされています。リポソームは、その修飾可能な構造と低い免疫原性により、このような課題に理想的に適しています。脂質化学、リガンド結合、ナノ製剤製造の技術的進歩により、より効率的な薬物のカプセル化、放出制御、受容体特異的ターゲティングが可能となっています。

最終用途の観点からは、がん領域が依然として最大の牽引役となっており、病院や専門クリニックでは化学療法の副作用を管理し、治療の忍容性を向上させるためにリポソーム療法が支持されています。消費者の行動も進化しており、患者や医師はナノメディシンを用いた治療法、特に全身的な副作用の少ない治療法をより広く受け入れています。LNPベースのCOVID-19ワクチンの成功は、脂質ベースのキャリアの使用を実証し、投資家の信頼を高め、様々な慢性疾患や感染症に対するリポソーム・プラットフォームの研究開発を急速に進めています。さらに、規制機関は、特に希少疾患やアンメットメディカルニーズに対して、リポソームをベースとした製剤に迅速なパスウェイや希少疾病用医薬品の指定を与えています。最後に、製薬企業、バイオベンチャー企業、研究機関の戦略的提携により、リポソームを利用した医薬品の開発が加速しており、市場競争は激しく、イノベーション主導の市場となっています。

セグメント

タイプ（リポソームドキソルビシン、リポソームパクリタキセル、リポソームアムホテリシンB、その他のタイプ）;アプリケーション（真菌感染療法、がん治療、その他のアプリケーション）

調査対象企業の例（注目43社）

  • Acuitas Therapeutics
  • Arrowhead Pharmaceuticals
  • Baxter International
  • Camurus AB
  • Catalent, Inc.
  • Evonik Industries AG
  • Fareva
  • Genmab
  • Gilead Sciences, Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Johnson & Johnson
  • Lonza Group
  • Merck KGaA
  • Novartis AG
  • Pacira BioSciences, Inc.
  • Pfizer Inc.
  • Recipharm AB
  • Takeda Pharmaceutical Company Limited
  • Vetter Pharma
  • Xiamen Amoytop Biotech Co., Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP35861

Global Targeted Liposomes Drug Delivery Market to Reach US$4.5 Billion by 2030

The global market for Targeted Liposomes Drug Delivery estimated at US$2.7 Billion in the year 2024, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 9.1% over the analysis period 2024-2030. Liposomal Doxorubicin, one of the segments analyzed in the report, is expected to record a 9.8% CAGR and reach US$2.3 Billion by the end of the analysis period. Growth in the Liposomal Paclitaxel segment is estimated at 10.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$709.4 Million While China is Forecast to Grow at 8.8% CAGR

The Targeted Liposomes Drug Delivery market in the U.S. is estimated at US$709.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$723.8 Million by the year 2030 trailing a CAGR of 8.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.4% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Global "Targeted Liposomes Drug Delivery" Market - Key Trends & Drivers Summarized

How Are Liposomes Unlocking Precision in Drug Delivery?

Targeted liposomes have emerged as one of the most sophisticated tools in precision medicine, revolutionizing how therapeutic compounds are delivered to specific cells or tissues. These nanoscale, lipid-based vesicles encapsulate drugs within aqueous cores or lipid bilayers, enhancing bioavailability, reducing toxicity, and allowing for controlled release. Unlike traditional drug delivery methods, which often disperse active agents systemically and indiscriminately, targeted liposomes use surface modifications-such as ligands, antibodies, peptides, or aptamers-to home in on receptors uniquely expressed on diseased cells, especially in cancer and inflammatory disorders.

This selectivity has turned liposomes into an invaluable platform in oncology, where they deliver chemotherapy agents like doxorubicin or paclitaxel directly to tumor sites, minimizing damage to healthy tissue. The FDA-approved formulations such as Doxil and Onivyde underscore their clinical viability and therapeutic impact. Liposomes also enable co-delivery of multiple drugs, paving the way for synergistic treatments that address drug resistance. Their biodegradability and low immunogenicity make them ideal for chronic and recurrent diseases requiring repeat dosing. This transformative ability to merge pharmacology with targeting precision is pushing targeted liposomes to the forefront of next-generation drug delivery systems.

What Innovations Are Enhancing Liposome Functionality and Targeting Accuracy?

Technological advances are rapidly refining how liposomes are constructed, functionalized, and deployed. The development of PEGylated liposomes-coated with polyethylene glycol-has extended circulation time in the bloodstream by preventing rapid clearance by the immune system. Meanwhile, ligand-conjugated liposomes are being engineered to bind with exquisite specificity to cellular markers overexpressed in diseases such as HER2+ breast cancer, EGFR-driven lung tumors, or CD44-expressing leukemias. This approach enhances intracellular uptake and improves drug retention at the target site.

Encapsulation techniques have also seen significant improvement. Remote loading methods, which exploit pH or ionic gradients, offer higher drug loading efficiency and stability compared to passive techniques. Additionally, stimuli-responsive liposomes-triggered by pH, temperature, enzymes, or external radiation-are enabling spatially and temporally controlled drug release, particularly useful in solid tumors where microenvironmental conditions differ from normal tissue. Microfluidic technologies are now enabling precision manufacturing of liposomes at scale with highly uniform size distributions, crucial for clinical efficacy and reproducibility. These scientific advancements are transforming liposomes into customizable, multifunctional nanocarriers capable of addressing previously intractable pharmacological challenges.

Where Are Targeted Liposomes Making the Greatest Clinical Impact Today?

The greatest clinical impact of targeted liposomes is currently being realized in oncology, infectious disease treatment, and rare genetic disorders. In cancer care, liposomal drug formulations are being used in the treatment of breast, ovarian, pancreatic, and liver cancers, where systemic chemotherapy often leads to dose-limiting toxicities. Liposomes not only shield normal cells but also allow for higher drug concentrations at the tumor site, increasing therapeutic efficacy. In hematological malignancies, liposome-based delivery of RNAi therapeutics is enabling gene silencing strategies that suppress oncogenes directly within diseased cells.

Beyond oncology, liposomes are gaining traction in the treatment of fungal and bacterial infections. Liposomal amphotericin B, for instance, has dramatically improved the safety profile of this potent antifungal drug, making it a mainstay in immunocompromised patients. In gene therapy and mRNA delivery, liposomes are being adapted into lipid nanoparticles (LNPs)-a close cousin-which played a pivotal role in the COVID-19 mRNA vaccines, proving their scalability and translational power. Additionally, rare disease treatments are beginning to adopt liposomal platforms to address lysosomal storage diseases and metabolic disorders, where precise intracellular delivery is critical. Pediatric applications are also expanding, as liposomes offer safer, lower-dose alternatives with improved compliance in young patients. The wide therapeutic applicability of targeted liposomes is making them a cornerstone of personalized, precision-driven pharmacotherapy.

The Growth in the Targeted Liposomes Drug Delivery Market Is Driven by Several Factors…

The growth in the targeted liposomes drug delivery market is driven by several factors rooted in pharmaceutical innovation, rising clinical demand for targeted therapies, and shifting regulatory and patient preferences. Chief among these is the increasing focus on personalized medicine, which requires delivery systems capable of targeting molecular subtypes of diseases with precision. Liposomes, owing to their modifiable structure and low immunogenicity, are ideally suited for such tasks. Technological advances in lipid chemistry, ligand conjugation, and nanoformulation manufacturing are allowing for more efficient drug encapsulation, controlled release, and receptor-specific targeting.

From an end-use perspective, oncology remains the largest driver, with hospitals and specialty clinics favoring liposomal therapies to manage chemotherapy side effects and improve treatment tolerability. Consumer behavior is also evolving, with patients and physicians showing greater acceptance of nanomedicine-based therapies, especially those that offer fewer systemic side effects. The success of LNP-based COVID-19 vaccines has validated the use of lipid-based carriers, increasing investor confidence and fast-tracking R&D in liposome platforms for various chronic and infectious diseases. Moreover, regulatory bodies are providing expedited pathways and orphan drug designations to liposome-based formulations, especially for rare diseases and unmet medical needs. Finally, strategic partnerships between pharmaceutical companies, biotech start-ups, and research institutions are accelerating the development of liposome-enabled drugs, making the market both highly competitive and innovation-driven.

SCOPE OF STUDY:

The report analyzes the Targeted Liposomes Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Other Types); Application (Fungal Infection Therapy, Cancer Therapy, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • Acuitas Therapeutics
  • Arrowhead Pharmaceuticals
  • Baxter International
  • Camurus AB
  • Catalent, Inc.
  • Evonik Industries AG
  • Fareva
  • Genmab
  • Gilead Sciences, Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Johnson & Johnson
  • Lonza Group
  • Merck KGaA
  • Novartis AG
  • Pacira BioSciences, Inc.
  • Pfizer Inc.
  • Recipharm AB
  • Takeda Pharmaceutical Company Limited
  • Vetter Pharma
  • Xiamen Amoytop Biotech Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Targeted Liposomes Drug Delivery - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Cancer and Chronic Diseases Propels Demand for Targeted Delivery Systems
    • Advancements in Liposome Formulation Technology Spur Innovation
    • Growing Interest in Precision Medicine Strengthens Market Opportunities
    • Regulatory Support for Nanomedicine Development Accelerates Product Approvals
    • Enhanced Bioavailability and Reduced Toxicity Drive Liposomal Adoption
    • Expansion of Liposomal Vaccines Market Boosts Industry Penetration
    • Sustained Growth in Injectable Drug Market Spurs Liposome Usage
    • Nanocarrier Platform Licensing Deals Open New Revenue Streams
    • Growing Role of AI in Lipid Nanoparticle Design Enhances Targeting Efficiency
    • Favorable Intellectual Property Landscape Supports Competitive Differentiation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Targeted Liposomes Drug Delivery Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Targeted Liposomes Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Targeted Liposomes Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Liposomal Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Liposomal Doxorubicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Liposomal Doxorubicin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Liposomal Paclitaxel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Liposomal Paclitaxel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Liposomal Paclitaxel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Liposomal Amphotericin B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Liposomal Amphotericin B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Liposomal Amphotericin B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Fungal Infection Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Fungal Infection Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Fungal Infection Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cancer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cancer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
  • JAPAN
    • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
  • CHINA
    • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
  • EUROPE
    • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Targeted Liposomes Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Targeted Liposomes Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
  • FRANCE
    • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
  • GERMANY
    • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Europe 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Targeted Liposomes Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Asia-Pacific 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Targeted Liposomes Drug Delivery by Type - Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of World 15-Year Perspective for Targeted Liposomes Drug Delivery by Type - Percentage Breakdown of Value Sales for Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B and Other Types for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Targeted Liposomes Drug Delivery by Application - Fungal Infection Therapy, Cancer Therapy and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of World 15-Year Perspective for Targeted Liposomes Drug Delivery by Application - Percentage Breakdown of Value Sales for Fungal Infection Therapy, Cancer Therapy and Other Applications for the Years 2015, 2025 & 2030

IV. COMPETITION